Astrazeneca Ab

Craig Robert Stewart

Stephen Connolly

Mark Richard Ebden

Iain Alastair Stewart Walters

Alan Robert Steven

Thomas Langer

Paula Margaret Tomlin

Andrew John Williams

Martin Hans Bohlin

Xiaolan Zheng

Alexander Hird

Qing Ye

Debasis Hazra

Simon Hardy

Andrew Stark

Cati Ferrar

Jan Koek

Iain Alastair Walters

Disclosed are intermediates and methods of synthesizing Compound 1. 

Synthesis of Mcl-1 inhibitor

A camsylate salt of (1r,1'R,4R)-4-methoxy-5&#x2033;-methyl-6&#x2032;-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3&#x2032;H-dispiro[cyclohexane-1,2&#x2032;-inden-1&#x2032;2&#x2032;-imidazole]-4&#x2033;-amine, pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating A&#x3b2;-related pathologies such as Alzheimer's Disease, Down's syndrome, &#x3b2;-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Camsylate salt

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound.  The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Compound

Growing community of inventors

Cheshire, United Kingdom

Craig Robert Stewart